Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Cogent Biosciences (COGT) FCF Margin (2017 - 2020)

Cogent Biosciences' FCF Margin history spans 4 years, with the latest figure at 3290.71% for Q3 2020.

  • Quarterly FCF Margin fell 229218.0% to 3290.71% in Q3 2020 from the year-ago period, while the trailing twelve-month figure was 455.47% through Dec 2020, down 27081.0% year-over-year, with the annual reading at 455.47% for FY2020, 27081.0% down from the prior year.
  • FCF Margin came in at 3290.71% for Q3 2020, down from 1576.52% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 55.32% in Q4 2019 to a low of 3290.71% in Q3 2020.
  • The 4-year median for FCF Margin is 364.37% (2018), against an average of 633.47%.
  • The largest YoY upside for FCF Margin was 26638bps in 2020 against a maximum downside of -229218bps in 2020.
  • Cogent Biosciences' FCF Margin stood at 309.75% in 2017, then increased by 23bps to 237.06% in 2018, then surged by 77bps to 55.32% in 2019, then tumbled by -5848bps to 3290.71% in 2020.
  • Per Business Quant, the three most recent readings for COGT's FCF Margin are 3290.71% (Q3 2020), 1576.52% (Q2 2020), and 112.26% (Q1 2020).